Ionis Pharmaceuticals (NASDAQ:IONS) EVP Kyle Jenne Sells 1,823 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Kyle Jenne sold 1,823 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $75.96, for a total value of $138,475.08. Following the completion of the transaction, the executive vice president directly owned 16,389 shares in the company, valued at approximately $1,244,908.44. This trade represents a 10.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ionis Pharmaceuticals Stock Performance

Shares of IONS stock opened at $77.53 on Wednesday. The firm has a 50 day moving average of $78.90 and a 200-day moving average of $64.33. The company has a market cap of $12.56 billion, a price-to-earnings ratio of -45.88 and a beta of 0.28. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $86.15.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. The business had revenue of $156.72 million for the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. Ionis Pharmaceuticals’s revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.95) earnings per share. On average, equities analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Key Headlines Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on IONS shares. Bank of America upped their price target on Ionis Pharmaceuticals from $86.00 to $97.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Stifel Nicolaus upped their target price on Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a “hold” rating in a research report on Monday, October 6th. Wells Fargo & Company increased their target price on Ionis Pharmaceuticals from $82.00 to $100.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Royal Bank Of Canada lifted their price target on shares of Ionis Pharmaceuticals from $82.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Finally, HC Wainwright upped their price objective on shares of Ionis Pharmaceuticals from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $87.05.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Steigerwald Gordon & Koch Inc. bought a new position in Ionis Pharmaceuticals during the 3rd quarter valued at $25,000. Golden State Wealth Management LLC lifted its position in shares of Ionis Pharmaceuticals by 198.4% during the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after buying an additional 250 shares in the last quarter. Mather Group LLC. purchased a new position in shares of Ionis Pharmaceuticals in the 3rd quarter worth approximately $27,000. Allworth Financial LP boosted its stake in shares of Ionis Pharmaceuticals by 231.8% in the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock worth $29,000 after buying an additional 517 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $38,000. 93.86% of the stock is owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.